|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Prototype sales | |||||
| Development contracts | |||||
| Total revenue | |||||
| Cost of Revenue | |||||
| Gross loss | |||||
| OPERATING EXPENSES: | |||||
| Research and development | |||||
| Selling and Marketing Expense | |||||
| General and Administrative Expense | |||||
| Impairment, Long-Lived Asset, Held-for-Use | |||||
| Total operating expenses | |||||
| LOSS FROM OPERATIONS | |||||
| OTHER INCOME (EXPENSE): | |||||
| Change in fair value of convertible note and warrant liabilities | |||||
| Interest income and other | |||||
| Interest expense and other | |||||
| Total other income (expense), net | |||||
| Loss before income tax | |||||
| Provision (benefit) for income tax | |||||
| Net loss | |||||
| Change in net unrealized gain (loss) on available-for-sale securities, net of tax | |||||
| Change in fair value due to instrument-specific credit risk, net of tax | |||||
| Net losses reclassified into income during the period, net of tax | |||||
| Comprehensive loss | |||||
| PER SHARE DATA | |||||
| Net loss per common share (basic and diluted) (in dollars per share) | |||||
| Weighted average common shares outstanding (basic and diluted) (in shares) | |||||
Loading...